Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 745

Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy

Dr Federico Cappuzzo speaks with ecancer at ESMO 2018 in Munich about the IMpower 130 trial, and the latest analysis of PFS and safety data from a randomised phase 3 study of carboplatin nab-paclitaxel with or without anti-PD-L1 atezolizumab as a first-line therapy in advanced non-squamous NSCLC.

From this trial of over 700 patients, he reports improved PFS and OS, with toxicity as expected from other trials of atezolizumab.

He also considers its utility as a treatment option in 2nd line therapies.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Breast Cancer CDK 4/6


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation